Nyxoah SA (NYXH)
About Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $64.8M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $64.8M
- Shares outstanding
- 46.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 5, 2021
Nyxoah SA (NYXH) Stock Price
- Trading 83% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Nyxoah SA.
Write a review
News about Nyxoah SA
News & sentiment via Polygon.io
Nyxoah SA: frequently asked questions
Is Nyxoah SA an American company?
Nyxoah SA is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Nyxoah SA publicly traded?
Yes — Nyxoah SA is a publicly traded company. Its stock trades under the ticker symbol NYXH on the NASDAQ.
What does Nyxoah SA do?
Nyxoah SA is an American Medical Devices company in the Health & Beauty sector.
